Avidity Biosciences Secures Accelerated Approval Pathway for Del-Brax in the U.S. and Launches Global Phase 3 Study for FSHD Treatment

Reuters

06-09

Avidity Biosciences Secures Accelerated Approval Pathway for Del-Brax in the U.S. and Launches Global Phase 3 Study for FSHD Treatment

Avidity Biosciences Inc. has announced that the U.S. FDA has opened the accelerated approval regulatory pathway for their drug del-brax, targeting facioscapulohumeral muscular dystrophy (FSHD). This development paves the way for a planned accelerated approval Biologics License Application $(BLA.AU)$ submission in the second half of 2026, following topline data from the FORTITUDE™ biomarker cohort in the second quarter of 2026. Additionally, Avidity has initiated the global, confirmatory Phase 3 FORWARD™ study, involving approximately 200 participants across North America, Europe, and Japan. This study aims to evaluate the efficacy of del-brax in improving functional mobility and strength in individuals with FSHD. The initiation of this study marks a critical step in Avidity's strategy to secure global approval for del-brax.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05504) on June 09, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542386470"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542386470\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542386470?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542386470","market":"us","top_or_hot":-1,"title":"Avidity Biosciences Secures Accelerated Approval Pathway for Del-Brax in the U.S. and Launches Global Phase 3 Study for FSHD Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avidity Biosciences Secures Accelerated Approval Pathway for Del-Brax in the U.S. and Launches Global Phase 3 Study for FSHD Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Avidity Biosciences Inc. has announced that the U.S. FDA has opened the accelerated approval regulatory pathway for their drug del-brax, targeting facioscapulohumeral muscular dystrophy (FSHD). This development paves the way for a planned accelerated approval Biologics License Application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> submission in the second half of 2026, following topline data from the FORTITUDE™ biomarker cohort in the second quarter of 2026. Additionally, Avidity has initiated the global, confirmatory Phase 3 FORWARD™ study, involving approximately 200 participants across North America, Europe, and Japan. This study aims to evaluate the efficacy of del-brax in improving functional mobility and strength in individuals with FSHD. The initiation of this study marks a critical step in Avidity's strategy to secure global approval for del-brax.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05504) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avidity Biosciences Secures Accelerated Approval Pathway for Del-Brax in the U.S. and Launches Global Phase 3 Study for FSHD Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvidity Biosciences Secures Accelerated Approval Pathway for Del-Brax in the U.S. and Launches Global Phase 3 Study for FSHD Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-09 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avidity Biosciences Secures Accelerated Approval Pathway for Del-Brax in the U.S. and Launches Global Phase 3 Study for FSHD Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Avidity Biosciences Inc. has announced that the U.S. FDA has opened the accelerated approval regulatory pathway for their drug del-brax, targeting facioscapulohumeral muscular dystrophy (FSHD). This development paves the way for a planned accelerated approval Biologics License Application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> submission in the second half of 2026, following topline data from the FORTITUDE™ biomarker cohort in the second quarter of 2026. Additionally, Avidity has initiated the global, confirmatory Phase 3 FORWARD™ study, involving approximately 200 participants across North America, Europe, and Japan. This study aims to evaluate the efficacy of del-brax in improving functional mobility and strength in individuals with FSHD. The initiation of this study marks a critical step in Avidity's strategy to secure global approval for del-brax.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05504) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL46Qzt5:1","article_id":"2542386470","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542386470","pubTimestamp":1749466856,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Avidity Biosciences Secures Accelerated Approval Pathway for Del-Brax in the U.S. and Launches Global Phase 3 Study for FSHD Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on June 09, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Avidity Biosciences获得Del-Brax在美国的加速批准途径，并启动FSHD治疗的全球3期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":0.9},"content_text":"Avidity Biosciences Secures Accelerated Approval Pathway for Del-Brax in the U.S. and Launches Global Phase 3 Study for FSHD Treatment\n    \n\n        Avidity Biosciences Inc. has announced that the U.S. FDA has opened the accelerated approval regulatory pathway for their drug del-brax, targeting facioscapulohumeral muscular dystrophy (FSHD). This development paves the way for a planned accelerated approval Biologics License Application $(BLA.AU)$ submission in the second half of 2026, following topline data from the FORTITUDE™ biomarker cohort in the second quarter of 2026. Additionally, Avidity has initiated the global, confirmatory Phase 3 FORWARD™ study, involving approximately 200 participants across North America, Europe, and Japan. This study aims to evaluate the efficacy of del-brax in improving functional mobility and strength in individuals with FSHD. The initiation of this study marks a critical step in Avidity's strategy to secure global approval for del-brax.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05504) on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}